Syndax製藥 SNDX 深 滬
等待開盤 11-01 09:30:00 美东时间
13.845
+0.455
+3.40%
華盛通- 最 高14.06
- 今 開13.34
- 成交量 259.85万股
- 最 低 13.30
- 昨 收 13.39
- 總市值 11.93亿
- 52周最高 22.50
- 市盈率 靜 --
- 換手率 3.02%
- 52周最低 8.58
- 委 比 -96.52%
- 總股本 8614.19万
- 歷史最高 29.86
- 量 比 0.46
- 振 幅 5.68%
- 歷史最低 3.39
- 每 手 1
- 風險率 2.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Syndax Pharmaceuticals's Earnings Outlook
Syndax Pharmaceuticals (NASDAQ:SNDX) will release its quarterly earnings report...
4分钟前
Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and管理团队will participate in several investor conferences in November 2025, including the UBS Global Healthcare Conference, Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference. Details on the fireside chats are provided, and webcasts will be available on the company's website. Syndax, a biopharmaceutical company focused on ...
10-30 11:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.
10-27 17:25
Syndax Pharmaceuticals Gains FDA Approval for Revuforj
The latest update is out from Syndax Pharmaceuticals ( ($SNDX) ). On October 24...
10-25 04:57
Why Is Syndax Stock Down Today?
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration.
10-25 04:07
Syndax gains additional indication for Revuforj in acute myeloid leukemia
The US FDA has approved Syndax Pharmaceuticals' (NASDAQ:SNDX) Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia in patients with a certain genetic mutation. The indication is for ...
10-25 01:53
FDA Approves Revumenib For Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible NPM1 Mutation
https://www.fda.gov/drugs/resources-information-approved-drugs/
10-25 01:08
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Where Syndax Pharmaceuticals Stands With Analysts
Syndax Pharmaceuticals (NASDAQ:SNDX) has been analyzed by 7 analysts in the las...
10-16 22:02
